Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

749.92 -3.49 (-0.46%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
The Stock Market Isn't Rocking This Month But The S&P 500 Is Headed For Its Best August In 3 Years
Kellanova and Fortinet are leading the S&P 500's August performance. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Visualizing The World’s Top 25 Companies By Market Cap
The world’s top 25 companies by market capitalization. 
Via Talk Markets
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results 
Via News Direct
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
Ozempic remains on top in the GLP-1 drug market -- but for how long? 
Via The Motley Fool
Check Out What Whales Are Doing With LLY
Via Benzinga
Eli Lilly Hits All-Time High, Gets Watchlist Trifecta: These Names Just Added To IBD 50, Other Top Stock Screens
Eli Lilly deserved landing on three top stock lists. The drug giant hit an all-time high Thursday and has surging earnings and revenue. 
Via Investor's Business Daily
Eli Lilly's Growth Rate Is Fantastic, but This Number Is Even Better
Eli Lilly's valuation may seem high right now, but with fast earnings growth, today's price could look like a deal in a few years. 
Via The Motley Fool
This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club
This leading pharmaceutical stock is flying under the radar right now. 
Via The Motley Fool
Wegovy Now Available Through Sesame's $249 Monthly Compounded Program Despite Supply Shortages
Sesame introduces an affordable weight loss program with compounded versions of Wegovy amid supply shortages. The program provides a $249 monthly alternative to expensive obesity treatments. 
Via Benzinga
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong bullish... 
Via Benzinga
Topics Economy
Exposures Supply Chain
Asia Mixed, European Markets Advance; Gold Stays Near All Time High While Dollar Gains - Global Markets Today While US Slept
US stock markets close lower, breaking 8-day winning streak as investors pause before economic symposium. Energy stocks decline, consumer staples gain. 
Via Benzinga
Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945?
The Big Pharma stock is up by more than 50% in 2024, but investment-bank analysts think it has more room to run. 
Via The Motley Fool
Why Eli Lilly Topped the Market on Tuesday
The company had very encouraging news to report about its hottest product. 
Via The Motley Fool
Biotech Bull Market: 3 Ways To Play It
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Wall Street Eases, Bonds Rises, US Dollar Falls To 8-Month Low: What's Driving Markets Tuesday?
It’s a relatively uneventful session on Wall Street, but with a slightly worsening risk sentiment as all U.S. equity indices traded in the red at around midday trading in New York. 
Via Benzinga
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Eli Lilly, An IBD 50 Stock, Nears Record High On Another Weight-Loss Win
The company tested tirzepatide in patients with prediabetes and obesity over three years. 
Via Investor's Business Daily
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates, 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Eli Lilly's Famed Obesity/Diabetes Treatment Tirzepatide Shows Potential To Cut Risk Of Developing Diabetes, Sustained Weight Loss Over 3 Years
Eli Lilly's SURMOUNT-1 three-year study reveals tirzepatide's effectiveness in reducing type 2 diabetes risk and achieving significant long-term weight loss in adults with pre-diabetes and obesity. 
Via Benzinga
1 Surefire Warren Buffett Index Fund Could Turn $400 Per Month Into $902,000
This reliable investment strategy has never failed to make money over 20-year holding periods. 
Via The Motley Fool
Three Biotech Stocks to Buy for the "Golden Age of Medicine"
Experts declare 'Golden Age of Medicine' with surge of new drug and medical discoveries. Biotech stocks like Eli Lilly and Sanofi are thriving. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Walmart Wins Bargain Games
The world's largest retailer is crushing the market. 
Via The Motley Fool
Telehealth Firm Hims & Hers Health Rides High On Demand for Copycat Weight Loss Drugs Amid Supply Shortages
Hims & Hers Health has seen its stock rise over 120% due to soaring demand for its affordable compounded GLP-1 weight-loss drugs, despite legal battles and safety concerns surrounding its... 
Via Benzinga
Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond
Impediments to growth are melting away while new opportunities begin to rise. 
Via The Motley Fool
Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
Eli Lilly has a lot going for it. 
Via The Motley Fool
Prediction: This Hypergrowth Company Could Be the Next Trillion-Dollar Stock
There's no stopping this incredible pharmaceutical stock. 
Via The Motley Fool
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
Should Novo Nordisk and Eli Lilly investors be worried about Roche? 
Via The Motley Fool
3 Companies Reporting Remarkable Results: Walmart, Eli Lilly, Cardinal Health
Several companies have stolen the spotlight throughout the earnings period, including Walmart, Cardinal Health, and Eli Lilly. All three posted robust results and upped guidance, as shares of each... 
Via Talk Markets
Is Madrigal Pharmaceuticals Stock a Buy?
The biotech could be worth a lot more in 10 years. 
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.